Antriabio Inc – Line of Credit (May 20th, 2014)

For value received, Drywave Technologies, Inc., with offices at 1281 E. Magnolia, Suite D 106, Fort Collins, Colorado 80524, as principal ("Borrower"), promises to pay to the order of AntriaBio, Inc., ("Lender") at 55 Broad St., 19th Floor, New York, NY or at such other address as Lender shall from time to time specify in writing, a principal sum of up to ONE MILLION DOLLARS ($1,000,000.00), in legal and lawful money of the United States of America, with interest on the outstanding principal from the date advanced until paid at the rate set out below. Interest shall be computed on a per annum basis of a year of 360 days and for the actual number of days elapsed, unless such calculation would result in a rate greater than the highest rate permitted by applicable law, in which case interest shall be computed on a per annum basis of a year of 365 days or 366 days in a leap year, as the case may be.

Antriabio Inc – The Warrant Represented by This Certificate and the Shares Issuable Upon Exercise Thereof Have Not Been Registered Under the Securities Act of 1933, as Amended (The "Securities Act") or the Securities Laws of Any State. This Warrant and the Shares Issuable Upon the Exercise Thereof Have Been Acquired for Investment and Not With a View to Distribution or Resale. This Warrant and the Shares Issuable Upon Exercise Thereof May Not Be Pledged, Sold, Assigned or Transferred Unless Such Transaction Is Made Pursuant to an Effective Registration Statement Filed Under the Securities Act or Applicable St (April 1st, 2014)

which shall not be such a day. Exercise shall be by presentation and surrender to the Company, or at the office of any transfer agent designated by the Company (the "Transfer Agent"), of (i) this Warrant, (ii) the attached exercise form properly executed, and (iii) a certified or official bank check for the Exercise Price for the number of shares of Common Stock issuable upon exercise of this Warrant (the "Warrant Shares") specified in the exercise form. If this Warrant is exercised in part only, the Transfer Agent shall, upon surrender of the Warrant, execute and deliver a new Warrant evidencing the rights of the Holder to purchase the remaining number of Warrant Shares purchasable hereunder. Upon receipt by the Company of this Warrant in proper form for exercise, accompanied by payment as aforesaid, the Holder shall be deemed to be the holder of record of the Common Stock issuable upon such exercise, notwithstanding that the stock transfer books of the Company shall then be closed or

Antriabio Inc – Termination Agreement (April 1st, 2014)

THIS TERMINATION AGREEMENT, dated March 26, 2014 (this "Agreement"), is entered into by and between AntriaBio, Inc., a Delaware corporation, (the "Company") and Steve R. Howe, an individual (the "Executive"). The Company and the Executive are collectively referred to herein as the "parties."

Antriabio Inc – Antriabio, Inc. Repayment Agreement (April 1st, 2014)

"THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"). THESE SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE COMPANY, (B) IF THE SECURITIES HAVE BEEN REGISTERED IN COMPLIANCE WITH THE REGISTRATION REQUIREMENTS UNDER THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS (C) IN COMPLIANCE WITH THE EXEMPTION FROM THE REGISTRATION REQUIREMENTS UNDER THE SECURITIES ACT IN ACCORDANCE WITH RULE 144 THEREUNDER, IF APPLICABLE, AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS, OR (D) IN A TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT OR ANY APPLICABLE STATE LAWS AND REGULATIONS GOVERNING THE OFFER AND SALE OF SECURITIES, AND THE HOLDER HAS, PRIOR TO SUCH SALE, FURNISHED TO THE COMPANY AN OPINION OF COUNSEL OF RECOGNIZED STANDING, OR OTHER EVIDENCE OF EXEMPTION, REASONABLY SATISFACTORY TO THE COMPANY. HEDG

Antriabio Inc – Contract (November 15th, 2013)

THIS CONVERTIBLE PROMISSORY NOTE (THE "NOTE") HAS NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR ANY STATE OR OTHER SECURITIES LAWS. NEITHER THIS NOTE NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF SUCH REGISTRATION, UNLESS THE TRANSACTION IS EXEMPT FROM, OR NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE ACT OR THE TRANSACTION IS IN COMPLIANCE WITH THE PROVISIONS OF REGULATION S OF THE ACT ("REGULATION S"). HEDGING TRANSACTIONS INVOLVING THIS SECURITY MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE ACT. THE HOLDER OF THIS NOTE BY ITS ACCEPTANCE HEREOF REPRESENTS THAT IT IS NOT A U.S. PERSON AND IS ACQUIRING THIS SECURITY IN AN OFFSHORE TRANSACTION PURSUANT TO RULE 903 OR 904 OF REGULATION S.

Antriabio Inc – Line of Credit (November 14th, 2013)

For value received, Drywave Technologies, Inc., with offices at 1281 E. Magnolia, Suite D 106, Fort Collins, Colorado 80524, as principal ("Borrower"), promises to pay to the order of AntriaBio, Inc., ("Lender") at 55 Broad St., 19th Floor, New York, NY or at such other address as Lender shall from time to time specify in writing, a principal sum of up to ONE MILLION DOLLARS ($1,000,000.00), in legal and lawful money of the United States of America, with interest on the outstanding principal from the date advanced until paid at the rate set out below. Interest shall be computed on a per annum basis of a year of 360 days and for the actual number of days elapsed, unless such calculation would result in a rate greater than the highest rate permitted by applicable law, in which case interest shall be computed on a per annum basis of a year of 365 days or 366 days in a leap year, as the case may be.

Antriabio Inc – AntriaBio Appoints Two Industry Leaders to Its Management Team (February 19th, 2013)

Menlo Park, CA - February 19th, 2013 - AntriaBio, Inc. is pleased to announce the appointment, on January 31, 2013, of two new members to its management team: Nevan Elam, AntriaBio's President and Chief Executive Officer and Sankaram Mantripragada, Ph.D, as AntriaBio's Chief Scientific Officer.

Antriabio Inc – Advisory Agreement (February 6th, 2013)

This Advisory Agreement ("Agreement") is effective as of July 2, 2012 by and between AntriaBio, Inc., a company incorporated under the laws of Delawre ("Client") and Konus Advisory Group, Inc., a Delaware corporation ("KAG"), for the purpose of setting forth the terms and conditions by which the Client will acquire KAG's services.

Antriabio Inc – Employment Agreement (February 6th, 2013)

THIS AGREEMENT is made and entered into effective as of April 1, 2012 by and between AntriaBio, Inc. a Delaware corporation, having an address of 55 Broad St., 19th Fl, New York, NY ("AntriaBio" or the "Company"), and Sankaram Mantripragada (the "Executive").

Antriabio Inc – The Reverse Merger Transaction to Be Closed Approximately January 31, 2013 as Contemplated by That Certain Share Exchange and Reorganization Agreement by and Among AntriaBio, Inc., a Delaware Corporation, the Company and the Company's Stockholders; Or (February 6th, 2013)

Antriabio Inc – The Reverse Merger Transaction to Be Closed Approximately January 31, 2013 as Contemplated by That Certain Share Exchange and Reorganization Agreement by and Among AntriaBio, Inc., a Delaware Corporation, the Company and the Company's Stockholders; Or (February 6th, 2013)

Antriabio Inc – Consultant Agreement (February 6th, 2013)

This Agreement is entered into as of July 1st, 2012, by and between AntriaBio, Inc., a Delaware Corporation, hereinafter referred to as COMPANY, and Hoyoung Huh, of Hannol Healthcare & Innovation, LLC, hereinafter referred to as Consultant.

Antriabio Inc – Employment Agreement (February 6th, 2013)

THIS AGREEMENT is made and entered into effective as of April 1, 2012 by and between AntriaBio, Inc., a Delaware corporation, having an address of 55 Broad St., 19th Fl, New York, NY ("AntriaBio" or the "Company"), and Mr. Steve R. Howe (the "Executive").